Adam B. Roberts

Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.

S. Frye, L. Kelly, C. Pepe-Ranney, 2015, Chemistry & biology.

SELECTIVE MODULATION OF THE MICROBIOME: EFFORTS TOWARD A NEW PARADIGM IN HUMAN THERAPEUTICS

Adam B. Roberts, 2014 .

Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential

S. Hazen, A. Lusis, V. Gogonea, 2018, Nature Medicine.

Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk.

O. Fiehn, S. Hazen, T. Lüscher, 2018, JCI insight.

Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity

M. Redinbo, S. Mani, M. Venkatesh, 2013, Molecular Pharmacology.

Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease

S. Hazen, J. Varga, Naseer Sangwan, 2020, Arteriosclerosis, thrombosis, and vascular biology.

Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

S. Hazen, A. Lusis, E. Org, 2015, Cell.

Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential

S. Hazen, A. Lusis, V. Gogonea, 2018, Nature Medicine.